goat polyclonal anti fn14 Search Results


94
R&D Systems goat polyclonal anti fn14
Goat Polyclonal Anti Fn14, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/Mouse+TWEAK+R%2FTNFRSF12+Antibody/pm25676319-90-35-43
Average 94 stars, based on 1 article reviews
goat polyclonal anti fn14 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Santa Cruz Biotechnology fn14
Comparison of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and <t>Fn14</t> mRNA levels of polymyositis (PM)/dermatomyositis (DM) and of healthy controls. Total RNA was isolated from fresh-frozen muscle tissue using TRIzol reagent, and fluorescent quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed. The glyceraldehyde-3-phosphate dehydrogenase ( GAPDH ) gene was used as an internal control. 2 −Δ CT was used to compute the expression values of the target genes. (A) TWEAK mRNA levels in muscle tissue of PM, DM and healthy controls. (B) Fn14 mRNA levels in muscle tissue of PM, DM and healthy controls. (C) Fn14 mRNA levels were compared in PM/DM patients sub-grouped based on the presence of oropharyngeal dysphagia. (D) Correlation of Fn14 mRNA levels with myositis disease activity assessment visual analog scales (MYOACT) muscle disease activity scores. (E) Correlation of Fn14 mRNA levels with MYOACT global disease activity scores. The data of unpaired samples were analyzed by using the Mann-Whitney U -test. Spearman’s correlation analysis was used to test for correlations. Horizontal bars indicate median levels.
Fn14, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/Fn14+Antibody/pmc03978894-87-31-44
Average 93 stars, based on 1 article reviews
fn14 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

91
Bio-Techne corporation 4403
Comparison of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and <t>Fn14</t> mRNA levels of polymyositis (PM)/dermatomyositis (DM) and of healthy controls. Total RNA was isolated from fresh-frozen muscle tissue using TRIzol reagent, and fluorescent quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed. The glyceraldehyde-3-phosphate dehydrogenase ( GAPDH ) gene was used as an internal control. 2 −Δ CT was used to compute the expression values of the target genes. (A) TWEAK mRNA levels in muscle tissue of PM, DM and healthy controls. (B) Fn14 mRNA levels in muscle tissue of PM, DM and healthy controls. (C) Fn14 mRNA levels were compared in PM/DM patients sub-grouped based on the presence of oropharyngeal dysphagia. (D) Correlation of Fn14 mRNA levels with myositis disease activity assessment visual analog scales (MYOACT) muscle disease activity scores. (E) Correlation of Fn14 mRNA levels with MYOACT global disease activity scores. The data of unpaired samples were analyzed by using the Mann-Whitney U -test. Spearman’s correlation analysis was used to test for correlations. Horizontal bars indicate median levels.
4403, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/4403/custom%404403%4026224570
Average 91 stars, based on 1 article reviews
4403 - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc rabbit polyclonal anti fn14 antibody
( A ) Whole kidney <t>Fn14</t> mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.
Rabbit Polyclonal Anti Fn14 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/TWEAK+Receptor%2FFn14+Antibody/pmc04926283-88-3-8
Average 93 stars, based on 1 article reviews
rabbit polyclonal anti fn14 antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Santa Cruz Biotechnology rhodamine conjugated donkey anti goat igg
( A ) Whole kidney <t>Fn14</t> mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.
Rhodamine Conjugated Donkey Anti Goat Igg, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/donkey+anti-goat+IgG-PE/pmc03978894-87-33-44
Average 94 stars, based on 1 article reviews
rhodamine conjugated donkey anti goat igg - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

99
Cell Signaling Technology Inc rabbit anti fn14 igg
( A ) Whole kidney <t>Fn14</t> mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.
Rabbit Anti Fn14 Igg, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/Anti-rabbit+IgG/pm26016896-135-0-5
Average 99 stars, based on 1 article reviews
rabbit anti fn14 igg - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

90
Kodak coomassie brilliant blue r-250
( A ) Whole kidney <t>Fn14</t> mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.
Coomassie Brilliant Blue R 250, supplied by Kodak, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/coomassie+brilliant+blue+g+250/10__1161_slash_01__atv__0000062883__93715__37-188-10-14
Average 90 stars, based on 1 article reviews
coomassie brilliant blue r-250 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

95
Santa Cruz Biotechnology goat polyclonal anti mcp 1
( A ) Whole kidney <t>Fn14</t> mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.
Goat Polyclonal Anti Mcp 1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/MCP-1/pmc03944020-95-20-24
Average 95 stars, based on 1 article reviews
goat polyclonal anti mcp 1 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
Bio-Techne corporation human tweak r/tnfrsf12 antibody
( A ) Whole kidney <t>Fn14</t> mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.
Human Tweak R/Tnfrsf12 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/Human+TWEAK+R%2FTNFRSF12+Antibody/bio-techne+corporation___af1199
Average 93 stars, based on 1 article reviews
human tweak r/tnfrsf12 antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Jackson Immuno goat anti mouse fc
( A ) Whole kidney <t>Fn14</t> mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.
Goat Anti Mouse Fc, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/Goat+Anti-Mouse+IgG%2C+Fc+fragment+specific/pm16888023-134-27-30
Average 94 stars, based on 1 article reviews
goat anti mouse fc - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Huabio Inc anti-fn14 et1611-93
( A ) Whole kidney <t>Fn14</t> mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.
Anti Fn14 Et1611 93, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/p+gp170+et1611+30+antibody/pmc11488420-80-53-55
Average 90 stars, based on 1 article reviews
anti-fn14 et1611-93 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc rabbit anti human fn14
Figure 1 Expression of PAI-1 and TF is associated with <t>Fn14</t> in human carotid atherosclerotic plaques. (A) Colocalization of Fn14 (green) and TF, PAI-1 or SMCs (brown). Pearson correlation showing the positive association between TF and Fn14 (B) or PAI-1 and Fn14 expression (C) in 26 human carotid atherosclerotic plaques.
Rabbit Anti Human Fn14, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/goat+polyclonal+anti+fn14/TWEAK+Receptor%2FFn14+Rabbit+mAb/pm20810696-69-38-43
Average 93 stars, based on 1 article reviews
rabbit anti human fn14 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


Comparison of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and Fn14 mRNA levels of polymyositis (PM)/dermatomyositis (DM) and of healthy controls. Total RNA was isolated from fresh-frozen muscle tissue using TRIzol reagent, and fluorescent quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed. The glyceraldehyde-3-phosphate dehydrogenase ( GAPDH ) gene was used as an internal control. 2 −Δ CT was used to compute the expression values of the target genes. (A) TWEAK mRNA levels in muscle tissue of PM, DM and healthy controls. (B) Fn14 mRNA levels in muscle tissue of PM, DM and healthy controls. (C) Fn14 mRNA levels were compared in PM/DM patients sub-grouped based on the presence of oropharyngeal dysphagia. (D) Correlation of Fn14 mRNA levels with myositis disease activity assessment visual analog scales (MYOACT) muscle disease activity scores. (E) Correlation of Fn14 mRNA levels with MYOACT global disease activity scores. The data of unpaired samples were analyzed by using the Mann-Whitney U -test. Spearman’s correlation analysis was used to test for correlations. Horizontal bars indicate median levels.

Journal: Arthritis Research & Therapy

Article Title: Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis

doi: 10.1186/ar4454

Figure Lengend Snippet: Comparison of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and Fn14 mRNA levels of polymyositis (PM)/dermatomyositis (DM) and of healthy controls. Total RNA was isolated from fresh-frozen muscle tissue using TRIzol reagent, and fluorescent quantitative reverse transcription polymerase chain reaction (RT-PCR) was performed. The glyceraldehyde-3-phosphate dehydrogenase ( GAPDH ) gene was used as an internal control. 2 −Δ CT was used to compute the expression values of the target genes. (A) TWEAK mRNA levels in muscle tissue of PM, DM and healthy controls. (B) Fn14 mRNA levels in muscle tissue of PM, DM and healthy controls. (C) Fn14 mRNA levels were compared in PM/DM patients sub-grouped based on the presence of oropharyngeal dysphagia. (D) Correlation of Fn14 mRNA levels with myositis disease activity assessment visual analog scales (MYOACT) muscle disease activity scores. (E) Correlation of Fn14 mRNA levels with MYOACT global disease activity scores. The data of unpaired samples were analyzed by using the Mann-Whitney U -test. Spearman’s correlation analysis was used to test for correlations. Horizontal bars indicate median levels.

Article Snippet: When double staining was carried out, anti-human TWEAK goat polyclonal antibodies (R&D systems) and anti-human Fn14 rabbit monoclonal antibodies (Abcam, Cambridge, UK) were used as primary antibodies for detecting TWEAK and Fn14, and Rhodamine-conjugated donkey anti-goat IgG and FITC-conjugated donkey anti-rabbit IgG (both from Santa Cruz Biotechnology) were used as secondary antibodies.

Techniques: Comparison, Isolation, Reverse Transcription, Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Control, Expressing, Activity Assay, MANN-WHITNEY

PM/DM patients with positive immunofluorescence staining for TWEAK and  Fn14

Journal: Arthritis Research & Therapy

Article Title: Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis

doi: 10.1186/ar4454

Figure Lengend Snippet: PM/DM patients with positive immunofluorescence staining for TWEAK and Fn14

Article Snippet: When double staining was carried out, anti-human TWEAK goat polyclonal antibodies (R&D systems) and anti-human Fn14 rabbit monoclonal antibodies (Abcam, Cambridge, UK) were used as primary antibodies for detecting TWEAK and Fn14, and Rhodamine-conjugated donkey anti-goat IgG and FITC-conjugated donkey anti-rabbit IgG (both from Santa Cruz Biotechnology) were used as secondary antibodies.

Techniques: Immunofluorescence, Staining

Expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and Fn14 in patients with polymyositis (PM)/dermatomyositis (DM) and in healthy controls. (A) Muscle biopsies from patients with PM/DM showed significantly higher levels of the TWEAK protein compared to those of healthy controls. Anti-human TWEAK polyclonal antibodies were used as the primary antibody for detection at a working concentration of 15 μg/ml. Rhodamine-conjugated anti-goat IgG was used as a second antibody. (B) In PM/DM biopsies, expression of the Fn14 protein was remarkably higher than that of healthy controls. Anti-human Fn14 monoclonal antibodies were used as the primary antibody for detection at a working concentration of 15 μg/ml. Rhodamine-conjugated anti-goat IgG was used as a second antibody. Each muscle section was analyzed in duplicate, and results from one representative experiment are shown. Negative controls were conducted by staining muscle biopsies with isotype control antibody, and no obvious immunofluorescence signal was observed in negative controls. (C) Serial muscle biopsy sections of PM/DM patients were applied for TWEAK immunofluorescence staining and H&E staining, and a representative picture of the same type of field is shown. (D) Muscle biopsy sections of PM/DM patient were applied for TWEAK and Fn14 immunofluorescence staining and a representative staining is shown. To ensure comparability, images were obtained using identical exposure settings for each channel. The TWEAK immunoreactivity is predominantly observed around the infiltrating monocytes, and a mild expression of TWEAK on the sarcolemma of muscle fibers is also visible. While Fn14 are mainly expressed on the sarcolemma of muscle fibers. Therefore, TWEAK and Fn14 are frequently found to be coexpressed in the same myofibers on overlay images. Magnification is 200 ×.

Journal: Arthritis Research & Therapy

Article Title: Expression of tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 in patients with polymyositis and dermatomyositis

doi: 10.1186/ar4454

Figure Lengend Snippet: Expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and Fn14 in patients with polymyositis (PM)/dermatomyositis (DM) and in healthy controls. (A) Muscle biopsies from patients with PM/DM showed significantly higher levels of the TWEAK protein compared to those of healthy controls. Anti-human TWEAK polyclonal antibodies were used as the primary antibody for detection at a working concentration of 15 μg/ml. Rhodamine-conjugated anti-goat IgG was used as a second antibody. (B) In PM/DM biopsies, expression of the Fn14 protein was remarkably higher than that of healthy controls. Anti-human Fn14 monoclonal antibodies were used as the primary antibody for detection at a working concentration of 15 μg/ml. Rhodamine-conjugated anti-goat IgG was used as a second antibody. Each muscle section was analyzed in duplicate, and results from one representative experiment are shown. Negative controls were conducted by staining muscle biopsies with isotype control antibody, and no obvious immunofluorescence signal was observed in negative controls. (C) Serial muscle biopsy sections of PM/DM patients were applied for TWEAK immunofluorescence staining and H&E staining, and a representative picture of the same type of field is shown. (D) Muscle biopsy sections of PM/DM patient were applied for TWEAK and Fn14 immunofluorescence staining and a representative staining is shown. To ensure comparability, images were obtained using identical exposure settings for each channel. The TWEAK immunoreactivity is predominantly observed around the infiltrating monocytes, and a mild expression of TWEAK on the sarcolemma of muscle fibers is also visible. While Fn14 are mainly expressed on the sarcolemma of muscle fibers. Therefore, TWEAK and Fn14 are frequently found to be coexpressed in the same myofibers on overlay images. Magnification is 200 ×.

Article Snippet: When double staining was carried out, anti-human TWEAK goat polyclonal antibodies (R&D systems) and anti-human Fn14 rabbit monoclonal antibodies (Abcam, Cambridge, UK) were used as primary antibodies for detecting TWEAK and Fn14, and Rhodamine-conjugated donkey anti-goat IgG and FITC-conjugated donkey anti-rabbit IgG (both from Santa Cruz Biotechnology) were used as secondary antibodies.

Techniques: Expressing, Concentration Assay, Bioprocessing, Staining, Control, Immunofluorescence

( A ) Whole kidney Fn14 mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.

Journal: Scientific Reports

Article Title: Non-canonical NFκB activation promotes chemokine expression in podocytes

doi: 10.1038/srep28857

Figure Lengend Snippet: ( A ) Whole kidney Fn14 mRNA expression. qRT-PCR. ( B ) Whole kidney Fn14 protein expression. Quantification of Western blot. ( C ) Whole kidney Fn14 and CCL21. Western blot. ( D ) Whole kidney CCL21mRNA expression. qRT-PCR. ( E )Whole kidney CCL21protein expression. Quantification of Western blot. Mean ± SEM of 5 rats, *p < 0.05 vs vehicle, **p < 0.001 vs vehicle.

Article Snippet: Primary antibodies were rabbit polyclonal anti-Fn14 antibody (1:1000, Cell Signaling, Hertfordshire, UK), rabbit polyclonal anti-p100/52 (1:500, Cell Signaling), rabbit polyclonal anti-CCL21 (1:500, Santa Cruz), goat polyclonal anti-CCL19 (1:500, R&D Systems), RANTES (1:500, Acris) and anti-NIK (1:500, Santa Cruz).

Techniques: Expressing, Quantitative RT-PCR, Western Blot

( A ) Fn14 and ( B ) CCL21 immunohistochemistry 10 days following PAN or vehicle injection. Note expression of Fn14 and CCL21 by WT1 positive (blue) podocytes (arrow) in PAN-treated rats (arrows). Original magnification x400. Detail x1000. Images representative of 6/7 animals per group.

Journal: Scientific Reports

Article Title: Non-canonical NFκB activation promotes chemokine expression in podocytes

doi: 10.1038/srep28857

Figure Lengend Snippet: ( A ) Fn14 and ( B ) CCL21 immunohistochemistry 10 days following PAN or vehicle injection. Note expression of Fn14 and CCL21 by WT1 positive (blue) podocytes (arrow) in PAN-treated rats (arrows). Original magnification x400. Detail x1000. Images representative of 6/7 animals per group.

Article Snippet: Primary antibodies were rabbit polyclonal anti-Fn14 antibody (1:1000, Cell Signaling, Hertfordshire, UK), rabbit polyclonal anti-p100/52 (1:500, Cell Signaling), rabbit polyclonal anti-CCL21 (1:500, Santa Cruz), goat polyclonal anti-CCL19 (1:500, R&D Systems), RANTES (1:500, Acris) and anti-NIK (1:500, Santa Cruz).

Techniques: Immunohistochemistry, Injection, Expressing

Figure 1 Expression of PAI-1 and TF is associated with Fn14 in human carotid atherosclerotic plaques. (A) Colocalization of Fn14 (green) and TF, PAI-1 or SMCs (brown). Pearson correlation showing the positive association between TF and Fn14 (B) or PAI-1 and Fn14 expression (C) in 26 human carotid atherosclerotic plaques.

Journal: Cardiovascular research

Article Title: TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells.

doi: 10.1093/cvr/cvq278

Figure Lengend Snippet: Figure 1 Expression of PAI-1 and TF is associated with Fn14 in human carotid atherosclerotic plaques. (A) Colocalization of Fn14 (green) and TF, PAI-1 or SMCs (brown). Pearson correlation showing the positive association between TF and Fn14 (B) or PAI-1 and Fn14 expression (C) in 26 human carotid atherosclerotic plaques.

Article Snippet: Plaques were cross-sectioned into 5-mm-thick pieces, dewaxed and rehydrated, and incubated overnight with goat anti-human TF (1:100 dilution; American Diagnostica Inc., Stamford, CT, USA), mouse antihuman PAI-1 (1:100 dilution, SC-8979; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or rabbit anti-human Fn14 (1:200 dilution; Cell Signaling Technology, Danvers, MA, USA).

Techniques: Expressing

Figure 2 TWEAK increases PAI-1 and TF expression in hASMCs. Quantitative real-time PCR analysis of PAI-1 and TF mRNA (18 h; A) and protein expression (24 h; B) in hASMCs treated with different concentrations of recombinant TWEAK. Quantitative real-time PCR analysis of PAI-1 and TF mRNA (18 h; C) and protein expression (24 h; D) in hASMCs treated with 0.1 mg/mL of recombinant TWEAK alone or in combination with anti- TWEAK (10 mg/mL), anti-Fn14 antibodies (5 mg/mL), or non-specific IgG (10 mg/mL). Values are normalized to GAPDH expression, and results are expressed as multiples of control values. Values shown are means+SD of three independent experiments. *P , 0.05 vs. control; †P , 0.05 vs. TWEAK; and ‡P , 0.05 vs. IgG.

Journal: Cardiovascular research

Article Title: TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells.

doi: 10.1093/cvr/cvq278

Figure Lengend Snippet: Figure 2 TWEAK increases PAI-1 and TF expression in hASMCs. Quantitative real-time PCR analysis of PAI-1 and TF mRNA (18 h; A) and protein expression (24 h; B) in hASMCs treated with different concentrations of recombinant TWEAK. Quantitative real-time PCR analysis of PAI-1 and TF mRNA (18 h; C) and protein expression (24 h; D) in hASMCs treated with 0.1 mg/mL of recombinant TWEAK alone or in combination with anti- TWEAK (10 mg/mL), anti-Fn14 antibodies (5 mg/mL), or non-specific IgG (10 mg/mL). Values are normalized to GAPDH expression, and results are expressed as multiples of control values. Values shown are means+SD of three independent experiments. *P , 0.05 vs. control; †P , 0.05 vs. TWEAK; and ‡P , 0.05 vs. IgG.

Article Snippet: Plaques were cross-sectioned into 5-mm-thick pieces, dewaxed and rehydrated, and incubated overnight with goat anti-human TF (1:100 dilution; American Diagnostica Inc., Stamford, CT, USA), mouse antihuman PAI-1 (1:100 dilution, SC-8979; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or rabbit anti-human Fn14 (1:200 dilution; Cell Signaling Technology, Danvers, MA, USA).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Recombinant, Control

Figure 3 Fn14 mediates PAI-1 and TF expression induced by TWEAK in hASMCs. Quantitative real-time PCR analysis of PAI-1 and TF mRNA (18 h; A) and protein expression (24 h; B) in hASMCs treated with 0.1 mg/mL of recombinant TWEAK alone or in combination with two different Fn14 siRNAs [Fn14 siRNA 1 (Invi- trogen) or Fn14 siRNA 2 (Santa Cruz Biotec.)]. Values were normal- ized to GADPH expression, and results are expressed as multiples of control values. Values shown are means +SD of three independent experiments. *P , 0.05 vs. control; †P , 0.05 vs. TWEAK; and ‡P , 0.05 vs. control siRNA.

Journal: Cardiovascular research

Article Title: TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells.

doi: 10.1093/cvr/cvq278

Figure Lengend Snippet: Figure 3 Fn14 mediates PAI-1 and TF expression induced by TWEAK in hASMCs. Quantitative real-time PCR analysis of PAI-1 and TF mRNA (18 h; A) and protein expression (24 h; B) in hASMCs treated with 0.1 mg/mL of recombinant TWEAK alone or in combination with two different Fn14 siRNAs [Fn14 siRNA 1 (Invi- trogen) or Fn14 siRNA 2 (Santa Cruz Biotec.)]. Values were normal- ized to GADPH expression, and results are expressed as multiples of control values. Values shown are means +SD of three independent experiments. *P , 0.05 vs. control; †P , 0.05 vs. TWEAK; and ‡P , 0.05 vs. control siRNA.

Article Snippet: Plaques were cross-sectioned into 5-mm-thick pieces, dewaxed and rehydrated, and incubated overnight with goat anti-human TF (1:100 dilution; American Diagnostica Inc., Stamford, CT, USA), mouse antihuman PAI-1 (1:100 dilution, SC-8979; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or rabbit anti-human Fn14 (1:200 dilution; Cell Signaling Technology, Danvers, MA, USA).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Recombinant, Control

Figure 4 TWEAK increases PAI-1 and TF activity in hASMCs. PAI-1 and TF activity in hASMCs treated with 0.1 mg/mL of recombinant TWEAK alone or in combination with anti-TWEAK (10 mg/mL), anti-Fn14 antibodies (5 mg/mL), or Fn14 siRNA after 24 h. Values shown are means +SD of three independent experiments. *P , 0.05 vs. control; and †P , 0.05 vs. TWEAK.

Journal: Cardiovascular research

Article Title: TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells.

doi: 10.1093/cvr/cvq278

Figure Lengend Snippet: Figure 4 TWEAK increases PAI-1 and TF activity in hASMCs. PAI-1 and TF activity in hASMCs treated with 0.1 mg/mL of recombinant TWEAK alone or in combination with anti-TWEAK (10 mg/mL), anti-Fn14 antibodies (5 mg/mL), or Fn14 siRNA after 24 h. Values shown are means +SD of three independent experiments. *P , 0.05 vs. control; and †P , 0.05 vs. TWEAK.

Article Snippet: Plaques were cross-sectioned into 5-mm-thick pieces, dewaxed and rehydrated, and incubated overnight with goat anti-human TF (1:100 dilution; American Diagnostica Inc., Stamford, CT, USA), mouse antihuman PAI-1 (1:100 dilution, SC-8979; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or rabbit anti-human Fn14 (1:200 dilution; Cell Signaling Technology, Danvers, MA, USA).

Techniques: Activity Assay, Recombinant, Control